. Author manuscript; available in PMC: 2013 Dec 1.

Published in final edited form as: Methods. 2013 Jun 29;64(2):10.1016/j.ymeth.2013.06.019. doi: 10.1016/j.ymeth.2013.06.019

Table 2.

Clinicopathologic characteristics of 40 patients participating in our CTC enumerations

Variable	Categories	Evaluable patients at UCLA (n=30)	Evaluable patients at CSMC (n=10)
Age at baseline	Median (Range)	70.5 (43–88)	67 (52–79)
Gleason Score	3+2	1 (3%)	0 (0%)
	3+3	1 (3%)	4 (40%)
	3+4	6 (20%)	4 (40%)
	4+3	5 (17%)	1 (10%)
	4+4	4 (13%)	1 (10%)
	4+5	2 (7%)	0 (0%)
	5+4	2 (7%)	0 (0%)
	5+5	1 (3%)	0 (0%)
	Unknown/Other	8 (27%)	0 (0%)
Stage	II	0 (0%)	6 (60%)
	III	0 (0%)	2 (20%)
	IV	30 (100%)	2 (20%)
Baseline PSA (ng/mL)	Median (Range)	50.25 (0.18– >5000)	5.6 (4.26–293.7)